Literature DB >> 32409959

Maspin suppresses cell invasion and migration in gastric cancer through inhibiting EMT and angiogenesis via ITGB1/FAK pathway.

Ning Wang1, Li-Li Chang2.   

Abstract

This study aims to investigate how Maspin affects the EMT and angiogenesis of gastric cancer (GC) cells via ITGB1/FAK pathway. Immunohistochemistry was used to evaluate the expressions of Maspin, ITGB1, FAK, E-cadherin, Vimentin, D2-40, and CD34 in GC and adjacent normal tissues from 160 patients. Then, the human GC cells with different degree of differentiation were transfected with Maspin CRISPR activation plasmid, ITGB1 siRNA and/or Maspin siRNA, followed by the following experiments, including qRT-PCR, western blotting, tube formation assay, Transwell assay and wound healing. GC tumor tissues manifested decreased Maspin with the activated ITGB1/FAK pathway. In tumor tissues, Maspin was negatively correlated with the expressions of ITGB1 and FAK, as well as Lauren's classification, differentiation degree, and TNM stage. Besides, Maspin was negatively related with lymphatic vessel density (LVD) and microvessel density (MVD), Vimentin and VEGF, but was positive correlated with E-cadherin. Maspin expression decreased, but ITGB1 and p-FAK expressions increased gradually in MKN-28 (well differentiated), SGC-7901 (moderate differentiated), and MKN-45 (poorly differentiated). Maspin CRISPR and ITGB1 siRNA increased E-cadherin with the decreased Vimentin, VEGF and bFGF, and the reductions of tube length. In comparison with the ITGB1 siRNA group, cells in the Maspin siRNA + ITGB1 siRNA group presented the more evident EMT and angiogenesis. Furthermore, ITGB1 siRNA reduced the malignancies of GC cells, which could be restored by Maspin siRNA. Maspin was downregulated in GC tissues, which could inhibit the EMT and angiogenesis by blocking the ITGB1/FAK pathway, thereby decreasing cell invasion and migration of GC.

Entities:  

Keywords:  Angiogenesis; EMT; FAK; Gastric cancer; ITGB1; Maspin

Mesh:

Substances:

Year:  2020        PMID: 32409959     DOI: 10.1007/s13577-020-00345-7

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  45 in total

1.  Expression of maspin in colorectal cancer.

Authors:  Yoshihisa Umekita; Masakazu Souda; Hiroki Yoshida
Journal:  In Vivo       Date:  2006 Nov-Dec       Impact factor: 2.155

2.  Roles of Fibroblast Activation Protein and Hepatocyte Growth Factor Expressions in Angiogenesis and Metastasis of Gastric Cancer.

Authors:  Li-Ming Gao; Fang Wang; Yue Zheng; Zhan-Zhao Fu; Lei Zheng; Lan-Lan Chen
Journal:  Pathol Oncol Res       Date:  2017-11-13       Impact factor: 3.201

3.  Conditional survival of patients with gastric cancer who undergo curative resection: A multi-institutional analysis in China.

Authors:  Pengliang Wang; Zhe Sun; Wei Wang; Jingyu Deng; Zhenning Wang; Han Liang; Zhiwei Zhou; Huimian Xu
Journal:  Cancer       Date:  2017-12-04       Impact factor: 6.860

4.  Analysis of co-expression networks for circular RNAs and mRNAs reveals that circular RNAs hsa_circ_0047905, hsa_circ_0138960 and has-circRNA7690-15 are candidate oncogenes in gastric cancer.

Authors:  Zhiyong Lai; Yang Yang; Yichao Yan; Tao Li; Yansen Li; Zhu Wang; Zhanlong Shen; Yingjiang Ye; Kewei Jiang; Shan Wang
Journal:  Cell Cycle       Date:  2017-11-09       Impact factor: 4.534

Review 5.  Gastric cancer treatment: similarity and difference between China and Korea.

Authors:  Kun Yang; Jian-Kun Hu
Journal:  Transl Gastroenterol Hepatol       Date:  2017-04-28

6.  Detection of circulating tumor cells by reverse transcriptase polymerase chain reaction of maspin in patients with breast cancer undergoing conventional-dose chemotherapy.

Authors:  R Sabbatini; M Federico; M Morselli; R Depenni; K Cagossi; M Luppi; G Torelli; V Silingardi
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

7.  Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.

Authors:  Kyoji Hirai; Kiyoshi Koizumi; Shuji Haraguchi; Tomomi Hirata; Iwao Mikami; Mitsuhiro Fukushima; Shigeki Yamagishi; Tetsuo Kawashima; Daisuke Okada; Kazuo Shimizu; Masashi Kawamoto
Journal:  Ann Thorac Surg       Date:  2005-01       Impact factor: 4.330

8.  Maspin (SERPINB5) is an obligate intracellular serpin.

Authors:  Sonia S Y Teoh; James C Whisstock; Phillip I Bird
Journal:  J Biol Chem       Date:  2010-02-01       Impact factor: 5.157

9.  Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells.

Authors:  Z Zou; A Anisowicz; M J Hendrix; A Thor; M Neveu; S Sheng; K Rafidi; E Seftor; R Sager
Journal:  Science       Date:  1994-01-28       Impact factor: 47.728

10.  TGFβ1-Induced LncRNA UCA1 Upregulation Promotes Gastric Cancer Invasion and Migration.

Authors:  Zhong-Kun Zuo; Yi Gong; Xiang-Heng Chen; Fei Ye; Zheng-Ming Yin; Qian-Ni Gong; Jiang-Sheng Huang
Journal:  DNA Cell Biol       Date:  2017-01-11       Impact factor: 3.311

View more
  4 in total

1.  Aldehyde dehydrogenase 3B2 promotes the proliferation and invasion of cholangiocarcinoma by increasing Integrin Beta 1 expression.

Authors:  Yue Wang; Kangshuai Li; Wei Zhao; Zengli Liu; Jialiang Liu; Anda Shi; Tianli Chen; Wentao Mu; Yunfei Xu; Chang Pan; Zongli Zhang
Journal:  Cell Death Dis       Date:  2021-12-14       Impact factor: 8.469

2.  DCBLD2 Affects the Development of Colorectal Cancer via EMT and Angiogenesis and Modulates 5-FU Drug Resistance.

Authors:  Pan Xie; Fu-Qiang Yuan; Ma-Sha Huang; Wei Zhang; Hong-Hao Zhou; Xi Li; Zhao-Qian Liu
Journal:  Front Cell Dev Biol       Date:  2021-05-19

Review 3.  Insights Into the Function and Clinical Application of HDAC5 in Cancer Management.

Authors:  Jun Yang; Chaoju Gong; Qinjian Ke; Zejun Fang; Xiaowen Chen; Ming Ye; Xi Xu
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

Review 4.  Issues of origin, morphology and clinical significance of tumor microvessels in gastric cancer.

Authors:  Marina A Senchukova
Journal:  World J Gastroenterol       Date:  2021-12-28       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.